OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in medicine
2019;6 132.

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives.

Nicolas Lepareur, Franck Lacœuille, Christelle Bouvry, François Hindré, Emmanuel Garcion, Michel Chérel, Nicolas Noiret, Etienne Garin, F F Russ Knapp
Author Information
  1. Nicolas Lepareur: Comprehensive Cancer Center Eugène Marquis Rennes, France.
  2. Franck Lacœuille: Angers University Hospital Angers, France.
  3. Christelle Bouvry: Comprehensive Cancer Center Eugène Marquis Rennes, France.
  4. François Hindré: Univ Angers Univ Nantes, Inserm, CNRS, CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes-Angers)-UMR 1232, ERL 6001, Nantes, France.
  5. Emmanuel Garcion: Univ Angers Univ Nantes, Inserm, CNRS, CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes-Angers)-UMR 1232, ERL 6001, Nantes, France.
  6. Michel Chérel: Univ Angers Univ Nantes, Inserm, CNRS, CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes-Angers)-UMR 1232, ERL 6001, Nantes, France.
  7. Nicolas Noiret: Univ Rennes CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Rennes, France.
  8. Etienne Garin: Comprehensive Cancer Center Eugène Marquis Rennes, France.
  9. F F Russ Knapp: Emeritus Medical Radioisotopes Program, ORNL (Oak Ridge National Laboratory), Oak Ridge, TN, United States.
PMID: 31259173 DOI: 10.3389/fmed.2019.00132

Abstract

Rhenium-188 (Re) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-life, which has been shown to be a very attractive candidate for use in therapeutic nuclear medicine. The high beta emission has an average energy of 784 keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is efficient for imaging and for dosimetric calculations. These key characteristics identify Re as an important therapeutic radioisotope for routine clinical use. Moreover, the highly reproducible on-demand availability of Re from the W/Re generator system is an important feature and permits installation in hospital-based or central radiopharmacies for cost-effective availability of no-carrier-added (NCA) Re. Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent a "theranostic pair." Thus, preparation and targeting of Re agents for therapy is similar to imaging agents prepared with Tc, the most commonly used diagnostic radionuclide. Over the last three decades, radiopharmaceuticals based on Re-labeled small molecules, including peptides, antibodies, Lipiodol and particulates have been reported. The successful application of these Re-labeled therapeutic radiopharmaceuticals has been reported in multiple early phase clinical trials for the management of various primary tumors, bone metastasis, rheumatoid arthritis, and endocoronary interventions. This article reviews the use of Re-radiopharmaceuticals which have been investigated in patients for cancer treatment, demonstrating that Re represents a cost effective alternative for routine clinical use in comparison to more expensive and/or less readily available therapeutic radioisotopes.

Keywords

Rhenium-188 bone pain palliation oncology peptides radioembolization radionuclide therapy radiopharmaceuticals

References

Nucl Med Biol. 1999 May;26(4):455-9 [PMID: 10382850]
Lancet. 1999 Sep 11;354(9182):931-5 [PMID: 10489968]
Eur J Nucl Med. 1999 Oct;26(10):1265-73 [PMID: 10541824]
Nucl Med Biol. 1999 Nov;26(8):973-6 [PMID: 10708313]
Eur J Nucl Med. 2000 Feb;27(2):123-30 [PMID: 10755716]
J Nucl Med. 2000 Apr;41(4):682-7 [PMID: 10768569]
Nucl Med Biol. 2000 Apr;27(3):309-14 [PMID: 10832088]
Cancer Biother Radiopharm. 1998 Oct;13(5):337-49 [PMID: 10851424]
J Nucl Med. 2000 Jul;41(7):1271-8 [PMID: 10914921]
Cancer Biother Radiopharm. 2000 Jun;15(3):261-5 [PMID: 10941533]
Eur J Nucl Med. 2000 Sep;27(9):1405-9 [PMID: 11007525]
Nuklearmedizin. 2000 Sep;39(6):146-51 [PMID: 11057405]
Clin Nucl Med. 2000 Nov;25(11):901-4 [PMID: 11079588]
Appl Radiat Isot. 2001 Mar;54(3):413-8 [PMID: 11214875]
Eur J Nucl Med. 2001 Mar;28(3):BP37-41 [PMID: 11315615]
Nucl Med Biol. 2001 Apr;28(3):319-26 [PMID: 11323244]
J Nucl Med. 2001 May;42(5):726-32 [PMID: 11337567]
Q J Nucl Med. 2001 Mar;45(1):18-26 [PMID: 11456371]
Blood. 2001 Aug 1;98(3):565-72 [PMID: 11468151]
Nucl Med Biol. 2001 Oct;28(7):835-44 [PMID: 11578906]
Clin Nucl Med. 2001 Nov;26(11):919-22 [PMID: 11595844]
Semin Nucl Med. 2001 Oct;31(4):330-41 [PMID: 11710775]
BMC Nucl Med. 2001;1(1):2 [PMID: 11734069]
Chem Rev. 1999 Sep 8;99(9):2269-92 [PMID: 11749482]
Nucl Med Biol. 2002 Jan;29(1):13-8 [PMID: 11786271]
Int J Appl Radiat Isot. 1979 Dec;30(12):725-7 [PMID: 118937]
Inorg Chem. 2002 Mar 25;41(6):1591-7 [PMID: 11896729]
Blood. 2002 Mar 15;99(6):2270-1 [PMID: 11902136]
Cancer Biother Radiopharm. 2002 Apr;17(2):151-63 [PMID: 12030109]
Ann Nucl Med. 2002 Apr;16(2):79-93 [PMID: 12043913]
Ann Acad Med Singapore. 2002 May;31(3):382-6 [PMID: 12061301]
Leuk Lymphoma. 2002 Nov;43(11):2125-31 [PMID: 12533037]
Appl Radiat Isot. 2003 May;58(5):551-5 [PMID: 12735971]
J Nucl Med. 2003 Jun;44(6):953-60 [PMID: 12791825]
J Clin Oncol. 2003 Aug 1;21(15):2869-75 [PMID: 12885803]
Br J Cancer. 2003 Aug 18;89(4):625-9 [PMID: 12915868]
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10942-7 [PMID: 12930899]
Semin Nucl Med. 1992 Jan;22(1):11-6 [PMID: 1375399]
Cancer Biother Radiopharm. 2003 Oct;18(5):719-26 [PMID: 14629820]
J Nucl Med. 2003 Dec;44(12):2033-8 [PMID: 14660730]
Semin Nucl Med. 2004 Jan;34(1):23-31 [PMID: 14735456]
J Nucl Med. 2004 Mar;45(3):500-7 [PMID: 15001694]
J Nucl Med. 2004 Apr;45(4):612-8 [PMID: 15073257]
Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):250-7 [PMID: 15129708]
Nucl Med Commun. 2004 Jul;25(7):691-9 [PMID: 15208496]
Nucl Med Commun. 2004 Sep;25(9):957-62 [PMID: 15319602]
J Cancer Res Clin Oncol. 2005 Jan;131(1):60-6 [PMID: 15449184]
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14865-70 [PMID: 15469923]
J Nucl Med. 2005 Jan;46(1):60-6 [PMID: 15632035]
Nucl Med Biol. 2005 Jan;32(1):59-65 [PMID: 15691662]
Appl Radiat Isot. 2005 May;62(5):745-50 [PMID: 15763481]
Cancer Biother Radiopharm. 2005 Apr;20(2):209-14 [PMID: 15869457]
Appl Radiat Isot. 2005 Sep;63(3):299-304 [PMID: 15963728]
Anticancer Res. 2005 Jul-Aug;25(4):2719-28 [PMID: 16080517]
J Nucl Med. 2005 Aug;46(8):1326-32 [PMID: 16085590]
J Nucl Med. 2005 Aug;46(8):1407-8; author reply 1407-8 [PMID: 16085601]
Br J Haematol. 2005 Aug;130(4):604-13 [PMID: 16098076]
Am J Clin Oncol. 2005 Oct;28(5):513-20 [PMID: 16199993]
Nucl Med Biol. 2005 Oct;32(7):695-700 [PMID: 16243644]
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):344-52 [PMID: 16333675]
Eur J Gastroenterol Hepatol. 2006 Feb;18(2):219-23 [PMID: 16394805]
J Vasc Interv Radiol. 2006 Jan;17(1):157-61 [PMID: 16415146]
Int J Pharm. 2006 Mar 9;310(1-2):125-30 [PMID: 16423478]
J Nucl Med. 2006 Feb;47(2):278-86 [PMID: 16455634]
Nucl Med Biol. 2006 Jan;33(1):81-9 [PMID: 16459262]
J Clin Invest. 1940 Mar;19(2):267-71 [PMID: 16694743]
Appl Radiat Isot. 2007 Jan;65(1):21-5 [PMID: 16725331]
Eur J Endocrinol. 2006 Oct;155(4):495-512 [PMID: 16990649]
Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [PMID: 17043623]
PLoS Med. 2006 Nov;3(11):e427 [PMID: 17090209]
Eur J Pharm Biopharm. 2007 Mar;65(3):282-8 [PMID: 17129715]
J Med Chem. 2007 Mar 22;50(6):1354-64 [PMID: 17315859]
Ann Oncol. 2007 Nov;18(11):1782-92 [PMID: 17434893]
Radiology. 2007 May;243(2):509-19 [PMID: 17456873]
Anticancer Agents Med Chem. 2007 May;7(3):367-77 [PMID: 17504162]
Nucl Med Commun. 2007 Aug;28(8):623-30 [PMID: 17625384]
Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1448-55 [PMID: 17692473]
J Clin Endocrinol Metab. 2007 Nov;92(11):4451-8 [PMID: 17698909]
Bioconjug Chem. 2007 Nov-Dec;18(6):1739-48 [PMID: 17907769]
Nucl Med Commun. 2008 Jan;29(1):66-75 [PMID: 18049099]
Arch Med Res. 2008 Jan;39(1):100-9 [PMID: 18068002]
Jpn J Clin Oncol. 2007 Dec;37(12):942-50 [PMID: 18094017]
Cancer Biol Ther. 2008 Mar;7(3):333-9 [PMID: 18094616]
Semin Nucl Med. 2008 Mar;38(2):S40-5 [PMID: 18243842]
Semin Nucl Med. 2008 Mar;38(2):S5-12 [PMID: 18243843]
Crit Rev Oncol Hematol. 2008 Sep;67(3):213-28 [PMID: 18387816]
Appl Radiat Isot. 2008 Dec;66(12):1876-80 [PMID: 18524608]
Nucl Med Biol. 2008 Jul;35(5):599-604 [PMID: 18589304]
Clin Exp Dermatol. 2008 Nov;33(6):745-9 [PMID: 18681873]
Eur J Nucl Med. 1991;18(6):408-31 [PMID: 1879447]
Appl Radiat Isot. 2009 Feb;67(2):234-9 [PMID: 19056284]
Nucl Med Biol. 2009 Jan;36(1):81-8 [PMID: 19181272]
Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1425-33 [PMID: 19319526]
Appl Radiat Isot. 2009 Jul-Aug;67(7-8):1162-6 [PMID: 19362007]
Curr Pharm Des. 2009;15(21):2453-62 [PMID: 19601842]
Antimicrob Agents Chemother. 2009 Nov;53(11):4860-8 [PMID: 19704133]
J Thorac Oncol. 2009 Dec;4(12):1550-4 [PMID: 19884860]
Br J Haematol. 2010 Mar;148(6):910-7 [PMID: 19995390]
Chem Rev. 2010 May 12;110(5):2903-20 [PMID: 20415476]
Appl Radiat Isot. 2010 Dec;68(12):2302-5 [PMID: 20637645]
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):948-55 [PMID: 20864271]
Dalton Trans. 2011 Feb 7;40(5):999-1010 [PMID: 21203624]
Phys Med Biol. 2011 Feb 7;56(3):703-19 [PMID: 21299006]
Ann Nucl Med. 2011 Jun;25(5):317-23 [PMID: 21336817]
Hum Gene Ther. 2011 Nov;22(11):1403-12 [PMID: 21488714]
Med Phys. 2011 Mar;38(3):1339-47 [PMID: 21520844]
Cancer Biother Radiopharm. 2011 Apr;26(2):237-44 [PMID: 21539455]
Biomaterials. 2011 Oct;32(28):6781-90 [PMID: 21705077]
Methods. 2011 Nov;55(3):258-70 [PMID: 21803158]
Phys Med Biol. 2011 Sep 7;56(17):5721-34 [PMID: 21841210]
J Nucl Med. 2011 Nov;52(11):1721-6 [PMID: 21976530]
Anticancer Agents Med Chem. 2012 Jun;12(5):428-61 [PMID: 22292757]
Curr Pharm Des. 2012;18(22):3313-20 [PMID: 22397732]
Int J Mol Imaging. 2012;2012:278306 [PMID: 22518301]
Curr Radiopharm. 2012 Jul;5(3):228-43 [PMID: 22642385]
Nucl Med Biol. 2013 Feb;40(2):182-9 [PMID: 23199569]
Int J Radiat Biol. 2013 May;89(5):346-55 [PMID: 23294030]
J Skin Cancer. 2013;2013:828329 [PMID: 23365757]
Int J Clin Exp Pathol. 2013;6(3):421-30 [PMID: 23411669]
Eur J Dermatol. 2013 Apr 1;23(2):183-8 [PMID: 23557628]
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8668-73 [PMID: 23610422]
Int J Mol Imaging. 2013;2013:290750 [PMID: 23653859]
Front Oncol. 2013 Sep 25;3:247 [PMID: 24093086]
Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):437-45 [PMID: 24116352]
Cancer Biother Radiopharm. 2014 Feb;29(1):1-11 [PMID: 24180669]
Nucl Med Biol. 2014 May;41 Suppl:e16-8 [PMID: 24342655]
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):80-8 [PMID: 24380048]
Front Oncol. 2014 Jan 14;3:324 [PMID: 24459634]
Int J Pharm. 2014 Apr 25;465(1-2):317-24 [PMID: 24560635]
G Ital Dermatol Venereol. 2014 Feb;149(1):115-21 [PMID: 24566572]
Appl Radiat Isot. 2014 Sep;92:25-31 [PMID: 24973465]
Med Sci Monit. 2014 Aug 02;20:1353-62 [PMID: 25086245]
Nucl Med Biol. 2015 Mar;42(3):317-22 [PMID: 25537725]
Nucl Med Biol. 2015 May;42(5):465-469 [PMID: 25662844]
Cancer Biother Radiopharm. 2015 Mar;30(2):47-71 [PMID: 25710506]
Nat Rev Cancer. 2015 Jun;15(6):347-60 [PMID: 25998714]
Biol Blood Marrow Transplant. 2015 Oct;21(10):1754-60 [PMID: 26001695]
Liver Cancer. 2015 Mar;4(1):6-15 [PMID: 26020025]
J Nucl Med. 2016 Mar;57(3):329-31 [PMID: 26514174]
Cancer Med. 2016 Jan;5(1):9-16 [PMID: 26625938]
Eur J Pharm Sci. 2016 Jul 30;90:96-101 [PMID: 26772897]
Appl Radiat Isot. 2016 Apr;110:87-99 [PMID: 26773820]
Inorg Chem. 2016 Feb 1;55(3):1124-33 [PMID: 26789775]
J Urol. 2016 Aug;196(2):382-91 [PMID: 26964917]
Biomaterials. 2016 Jul;94:31-44 [PMID: 27088408]
Semin Nucl Med. 2016 Jul;46(4):324-39 [PMID: 27237442]
Nuklearmedizin. 2016 Sep 26;55(5):188-95 [PMID: 27443809]
Ther Adv Med Oncol. 2016 Jul;8(4):294-304 [PMID: 27482288]
Bone. 2016 Oct;91:159-79 [PMID: 27496068]
Oncol Rep. 2016 Oct;36(4):2289-97 [PMID: 27573304]
Sci Rep. 2016 Sep 21;6:33511 [PMID: 27649935]
Nucl Med Biol. 2016 Dec;43(12):788-801 [PMID: 27694057]
Molecules. 2016 Sep 30;21(10): [PMID: 27706035]
PLoS One. 2016 Oct 14;11(10):e0164626 [PMID: 27741267]
Nucl Med Biol. 2016 Dec;43(12):812-817 [PMID: 27744117]
J Neurooncol. 2017 Jan;131(1):49-58 [PMID: 27783195]
Clin Exp Metastasis. 2017 Jan;34(1):1-10 [PMID: 27988895]
Cancer Biother Radiopharm. 2017 Feb;32(1):16-23 [PMID: 28118029]
J Nucl Med. 1988 Jan;29(1):33-8 [PMID: 2826723]
Int J Mol Sci. 2017 Apr 25;18(5):null [PMID: 28441355]
Dermatol Ther. 2017 Sep;30(5):null [PMID: 28621443]
Sci Rep. 2017 Jun 27;7(1):4278 [PMID: 28655913]
J Exp Clin Cancer Res. 2017 Aug 11;36(1):108 [PMID: 28800754]
J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S [PMID: 28864619]
Nucl Med Commun. 2018 Jan;39(1):1-2 [PMID: 28914686]
Biomed Res Int. 2017;2017:5923609 [PMID: 28951872]
Theranostics. 2017 Oct 12;7(18):4517-4536 [PMID: 29158842]
Target Oncol. 2018 Apr;13(2):189-203 [PMID: 29423595]
Sci Rep. 2018 Apr 3;8(1):5466 [PMID: 29615812]
Nucl Med Commun. 2018 Oct;39(10):957-959 [PMID: 30086075]
World J Nucl Med. 2018 Oct-Dec;17(4):228-235 [PMID: 30505219]
EJNMMI Phys. 2018 Dec 7;5(1):30 [PMID: 30523435]
Clin Genitourin Cancer. 2019 Apr;17(2):e281-e292 [PMID: 30555024]
Anticancer Res. 2019 Jan;39(1):183-190 [PMID: 30591457]
Biomed Res Int. 2018 Dec 31;2018:1435302 [PMID: 30687734]
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1506-1517 [PMID: 30715571]
Int J Rad Appl Instrum B. 1986;13(4):465-77 [PMID: 3793504]
Nucl Med Commun. 1993 Nov;14(11):995-7 [PMID: 8290173]
Nucl Med Commun. 1993 Mar;14(3):197-203 [PMID: 8384352]
Appl Radiat Isot. 1997 Mar;48(3):305-9 [PMID: 9116651]
J Nucl Med. 1998 Jan;39(1):34-42 [PMID: 9443735]
J Nucl Med. 1998 Apr;39(4):659-63 [PMID: 9544677]
Nucl Med Commun. 1998 Feb;19(2):173-81 [PMID: 9548202]
Eur J Nucl Med. 1998 Jun;25(6):613-21 [PMID: 9618576]
J Nucl Med. 1998 Oct;39(10):1752-7 [PMID: 9776282]
J Biomed Mater Res. 1998 Dec 15;42(4):617-25 [PMID: 9827687]
Journal Article Review

Word Cloud

Similar Articles

Cited By